<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017350</url>
  </required_header>
  <id_info>
    <org_study_id>2021-04-028-003</org_study_id>
    <nct_id>NCT05017350</nct_id>
  </id_info>
  <brief_title>Hemostasis Using Radiofrequency Ablation for Track Bleeding</brief_title>
  <official_title>Hemostasis Using Radiofrequency Ablation for Track Bleeding After Liver Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoung Doo Song</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the usefulness of hemostasis using radiofrequency ablation for&#xD;
      track bleeding that has occurred after percutaneous biopsy of the liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To evaluate the usefulness of hemostasis using radiofrequency ablation for track&#xD;
      bleeding after percutaneous liver biopsy.&#xD;
&#xD;
      Method:&#xD;
&#xD;
        -  Enroll patients who continue to bleed despite conservative treatment for track bleeding&#xD;
           that has occurred after liver biopsy.&#xD;
&#xD;
        -  Radiofreqeuncy ablation: Under monitoring vital signs and controlling pain with&#xD;
           intravenous agents, the electrode is inserted into the bleeding focus. The bleeding&#xD;
           focus is ablated.&#xD;
&#xD;
        -  Hemostasis is evaluated by ultrasound (right after radiofrequency ablation), CT scan&#xD;
           (after the radiofrequency ablation), and ultrasound (the day after radiofrequency&#xD;
           ablation)&#xD;
&#xD;
        -  If hemostasis fails using radiofrequency ablation, transarterial hepatic embolization is&#xD;
           performed immediately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemostasis rate</measure>
    <time_frame>immediately after radiofrequency ablation</time_frame>
    <description>success rate of hemostasis using radiofrequency ablation on CT taken after radiofrequency ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
    <time_frame>immediately after radiofrequency ablation</time_frame>
    <description>complication rate associated with radiofrequency ablation on CT taken after radiofrequency ablation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Radiofrequency ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hemostasis using radiofrequency ablation for track bleeding</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>Under the ultrasound guidance, the electrode is inserted into the bleeding focus of the liver and the bleeding focus is ablated.</description>
    <arm_group_label>Radiofrequency ablation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ultrasound guided percutaneous liver biopsy at Samsung Medical Center&#xD;
&#xD;
          -  Track bleeding after biopsy&#xD;
&#xD;
          -  Persistent track bleeding even after conservative management&#xD;
&#xD;
          -  Consent to this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not consent to this study&#xD;
&#xD;
          -  &lt;20 years old or &gt;=80 years old&#xD;
&#xD;
          -  Contraindication to radiofrequency ablation&#xD;
&#xD;
          -  Radiofrequency ablation for track bleeding is not technically possible.&#xD;
&#xD;
          -  Unstable vital signs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoung Doo Song, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyoung Doo Song, Professor</last_name>
    <phone>82-2-3410-2518</phone>
    <email>kd3893.song@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Woo Lee, Professor</last_name>
    <email>mw2542.lee@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyoung Doo Song, Professor</last_name>
      <email>kd3893.song@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Kyoung Doo Song</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>track bleeding</keyword>
  <keyword>radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

